U.S. Personal Products Stock News

NYSE:VVV
NYSE:VVVSpecialty Retail

Assessing Valvoline (VVV) Valuation After Recent Share Price Momentum

Valvoline overview and recent stock performance Valvoline (VVV) has drawn investor attention after recent trading, with the share price last closing at $37.50. Over the past month, the stock shows a 14.6% return and about 23% in the past 3 months. See our latest analysis for Valvoline. The recent 30 day share price return of 14.6% and 90 day gain of 22.7% suggest momentum has been building, even though the 1 year total shareholder return sits at 6.4%. If Valvoline’s move has you looking wider...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

Assessing Sterling Infrastructure (STRL) Valuation After Recent Share Price Volatility

Event overview and recent share performance Sterling Infrastructure (STRL) is back on investors’ radar after a sharp single day move, with the stock down about 4% over the latest session and 9.6% over the past week. Those short term swings contrast with gains of 16% over the past month, 28.5% in the past 3 months and a 30.2% year to date return, prompting fresh attention on what is driving sentiment. See our latest analysis for Sterling Infrastructure. Short term, the recent 1 day share price...
NYSE:SE
NYSE:SEMultiline Retail

Is The Market Overreacting To Sea (SE) After The Recent Share Price Slide

If you are wondering whether Sea's current share price offers value for your money, this article will walk through what the market might be pricing in and how that lines up with the underlying business. Sea's share price closed at US$87.82, with returns of an 18% decline over 7 days, a 24.6% decline over 30 days, a 33.2% decline year to date and a 33.6% decline over the past year, while the 3 year return sits at 9.7% and the 5 year return at a 61.6% decline. These moves have put Sea back on...
NYSE:TOST
NYSE:TOSTDiversified Financial

Assessing Toast (TOST) Valuation After Fresh Coverage On Its Restaurant Platform Role

Fresh coverage has pushed Toast (TOST) back into focus, spotlighting its role as a core integration layer across 156,000 restaurant locations that process US$51.5b in payments, alongside new enterprise wins and international expansion. See our latest analysis for Toast. Fresh coverage around Toast's role as a core restaurant platform arrives after a mixed stretch for the stock, with a 1-day share price return of 5.59% and 7-day share price return of 13.84%, set against a 30-day share price...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

uniQure (QURE) Is Down 62.4% After AMT-130 Lawsuits Challenge Huntington’s Disclosure Timeline - What's Changed

uniQure N.V. has reported full-year 2025 results, with revenue of US$16.1 million versus US$27.12 million a year earlier and a net loss of US$198.97 million versus US$239.56 million, alongside rising investor scrutiny over its Huntington’s disease program. Multiple securities class action lawsuits now allege that uniQure misrepresented aspects of its AMT-130 Huntington’s trial design and regulatory timelines, intensifying focus on how core pipeline disclosures align with future regulatory...
NasdaqCM:IMNM
NasdaqCM:IMNMBiotechs

Assessing Immunome (IMNM) Valuation After Pipeline Progress And Narrowed Annual Net Loss

Why Immunome’s latest update caught investor attention Immunome (IMNM) has been in focus after management highlighted progress across its oncology pipeline, including top-line Phase 3 results for Varegacestat in desmoid tumors, alongside full year 2025 earnings that showed a smaller net loss. See our latest analysis for Immunome. Despite the clinical and earnings updates, Immunome’s share price has eased recently, with a 30 day share price return of a 12.51% decline, even though the 90 day...
NYSE:GIS
NYSE:GISFood

A Look At General Mills (GIS) Valuation After EPS Guidance Cut And Profitability Headwinds

General Mills (GIS) has come under closer investor scrutiny after cutting its full-year EPS guidance to a 16% to 20% decline, along with sharp drops in net income and operating income tied to affordability pressures. See our latest analysis for General Mills. Those guidance cuts and profit pressures have come alongside softer recent trading, with a 1-day share price return of 1.29% decline, 30-day share price return of 3.72% decline, and a 1-year total shareholder return of 23.51% loss,...
NYSE:BBAI
NYSE:BBAIIT

BigBear.ai Holdings BBAI Q4 Loss Revives Bearish Narratives On Persistent Unprofitability

BigBear.ai Holdings (BBAI) just posted its FY 2025 numbers, closing out the year with Q4 revenue of US$27.3 million and a basic EPS loss of US$0.01, alongside a trailing twelve month basic EPS loss of US$0.82 on revenue of US$127.7 million. Over recent quarters the company has seen quarterly revenue move from US$43.8 million in Q4 2024 to US$27.3 million in Q4 2025. Basic EPS has ranged from a loss of US$0.58 in Q4 2024 to a small profit of US$0.01 in Q3 2025, before slipping back into a...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

Nuvation Bio (NUVB) Q4 Revenue Surge Tests Bullish Growth Narrative Against Ongoing Losses

Nuvation Bio FY 2025 Earnings Snapshot Nuvation Bio (NUVB) has wrapped up FY 2025 with fourth quarter revenue of about US$41.9 million and a basic EPS loss of US$0.11, as the market weighs solid top line figures against continued bottom line pressure. The company has seen revenue move from US$5.7 million in Q4 2024 to US$41.9 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.15 in Q4 2024 to a loss of US$0.11 in Q4 2025 and a trailing twelve month basic EPS loss of...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story

Halozyme Therapeutics (NasdaqGS:HALO) has agreed to acquire Hypercon and several biotech startups, expanding its drug delivery and platform capabilities. The Hypercon deal extends Halozyme’s intellectual property coverage into the 2040s, supporting long term use of its core technologies. The company recently reported new ENHANZE-enabled collaborations and fresh global regulatory approvals for subcutaneous formulations using its platform. Halozyme Therapeutics, trading at $69.4, has recorded...
NYSE:DBRG
NYSE:DBRGCapital Markets

Assessing DigitalBridge Group (DBRG) Valuation After A Sharp 90 Day Share Price Rally

Without a clear headline event, DigitalBridge Group (DBRG) still attracts attention as a digital infrastructure focused asset manager, with recent returns and fundamentals giving investors several angles to reassess the stock’s current pricing. See our latest analysis for DigitalBridge Group. At a share price of US$15.46, DigitalBridge Group’s recent 90 day share price return of 56.8% contrasts with a 42.35% 1 year total shareholder return and a 5 year total shareholder return of 41.5%. This...
NYSE:PGR
NYSE:PGRInsurance

Is It Time To Reassess Progressive (PGR) After Its Recent Share Price Pullback?

If you are wondering whether Progressive's share price still reflects its true worth after a strong multi year run, starting with the current valuation story can help you frame your next move. The stock last closed at US$213.35, with returns of 3.5% over the past week, 2.6% over the past month, 0.6% year to date, a 19.8% decline over the past year, and 61.2% and 164.7% over the past three and five years respectively. Recent headlines around Progressive have focused on the company as a major...
NasdaqGS:WIX
NasdaqGS:WIXIT

Wix ChatGPT Integration Puts AI Website Creation At Center Of Growth Story

Wix.com (NasdaqGS:WIX) has launched a new Wix app inside ChatGPT. The integration lets users create and manage websites using conversational prompts. The collaboration connects OpenAI’s ChatGPT with Wix tools for website building and business operations. Wix.com, known for its website creation and business tools, is moving deeper into AI driven experiences through this new ChatGPT integration. By putting a Wix app directly inside ChatGPT, the company is tying its core website builder and...
NYSE:UI
NYSE:UICommunications

Assessing Ubiquiti (UI) Valuation After Zacks Rank 1 Upgrade And Earnings Estimate Revisions

Ubiquiti (UI) recently caught investors’ attention after being upgraded to a Zacks Rank #1. This move is tied to higher earnings estimates and renewed focus on how its current valuation stacks up. See our latest analysis for Ubiquiti. Ubiquiti’s share price has moved to US$762.35, with a 38.25% 1 month share price return and 35.24% 3 month share price return, while its 1 year total shareholder return of 137.14% points to strong longer term momentum around the recent earnings upgrade. If...
NasdaqGS:CME
NasdaqGS:CMECapital Markets

How CME’s 24/7 Crypto Derivatives Push and New Altcoin Futures At CME Group (CME) Has Changed Its Investment Story

CME Group has recently expanded its regulated cryptocurrency futures suite to include Cardano, Chainlink, and Stellar, and announced plans for 24/7 crypto futures and options trading access starting May 29, pending regulatory approval. This push deeper into digital asset derivatives signals CME’s intent to become a core venue for institutional and retail crypto risk management under regulatory oversight. We’ll now examine how CME’s move to 24/7 crypto derivatives trading could reshape its...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Astera Labs (ALAB) Valuation Check As AI Connectivity Expansion Draws Investor Attention

Astera Labs (ALAB) is back in focus after its move into advanced optical interconnects, marked by the aiXscale Photonics acquisition, the establishment of an Israel Design Center, and a growing role in the UALink consortium with major hyperscalers. See our latest analysis for Astera Labs. Despite the recent flurry of AI infrastructure announcements, Astera Labs’ share price has pulled back. The 1-day share price return shows an 8.92% decline and the 30-day share price return shows a 27.10%...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

AST SpaceMobile TELUS Deal Highlights Commercial Shift And Valuation Tension

AST SpaceMobile (NasdaqGS:ASTS) has signed a commercial agreement with TELUS to deliver space based cellular broadband to remote parts of Canada. The deal includes TELUS investing in AST SpaceMobile's satellite infrastructure and taking an equity stake in the company. AST SpaceMobile reports that it has moved from an R&D focus to commercial operations, with new satellite deployments and contracts across commercial and defense customers. For investors watching NasdaqGS:ASTS, this update...
NYSE:AIG
NYSE:AIGInsurance

A Look At American International Group’s Valuation After Strong Q4 Earnings And 2026 Capital Return Plans

American International Group (AIG) recently reported a 51% year over year increase in Q4 adjusted after tax income, along with plans for at least US$1 billion in 2026 share repurchases and low to mid teens net premiums written growth. See our latest analysis for American International Group. AIG’s recent Q4 earnings jump and capital return plans come after a mixed year for the stock, with a 5.58% 1 month share price return and a 1.13% 1 year total shareholder return. The shorter term share...
NYSE:AI
NYSE:AISoftware

C3.ai Reshapes Defense Role And Restructuring Outlook For Investors

C3.ai (NYSE:AI) has expanded its role as a defense technology provider, supplying AI tools that support US military operations as geopolitical tensions rise. The company is undergoing internal restructuring under new leadership, including a cost-cutting program and workforce reductions aimed at refocusing the business. These shifts are reshaping C3.ai's position in defense and enterprise AI, with potential implications for risk profile, growth drivers, and capital allocation. C3.ai is...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

ImmunityBio (IBRX) Is Down 13.4% After ANKTIVA Data And New EMEA Deals - What's Changed

In late February 2026, ImmunityBio reported strong interim Phase 2 data for ANKTIVA plus BCG in BCG-naïve non-muscle invasive bladder cancer and advanced international commercialization through new approvals and partnerships across Europe and the Middle East. This combination of earlier-than-planned trial enrollment completion, statistically significant response durability, and rapid global rollout meaningfully strengthens ANKTIVA’s role at the center of ImmunityBio’s business. We will now...
NYSE:VZ
NYSE:VZTelecom

Verizon Taps 5G V2X To Expand Connected Mobility Revenue Potential

Verizon Communications (NYSE:VZ), Aptiv, and Wind River unveiled a vehicle-to-everything (V2X) connected driving solution using Verizon’s 5G and edge compute infrastructure. The proof of concept focuses on real-time sharing of sensor data between vehicles through standardized APIs and widely available hardware. The collaboration highlights potential support for safety features such as automatic emergency braking and cooperative driving functions. For you as an investor, this matters because...
NasdaqGS:EWTX
NasdaqGS:EWTXPharmaceuticals

Edgewise Therapeutics (EWTX) Is Down 6.8% After Wider 2025 Losses And New BMD Data Plans – Has The Bull Case Changed?

Edgewise Therapeutics reported a fourth-quarter 2025 net loss of US$50.22 million and a full-year 2025 net loss of US$167.8 million, alongside widening losses per share from continuing operations compared with the prior year. The company also highlighted upcoming presentations of new sevasemten data in Becker muscular dystrophy at the Muscular Dystrophy Association Clinical and Scientific Conference, underlining how clinical progress remains central to its story despite continued...
NasdaqGS:DBX
NasdaqGS:DBXSoftware

Why Dropbox (DBX) Is Up 7.8% After Earnings Beat, Major Buybacks and New ESOP Shelf Registration

In February 2026, Dropbox, Inc. reported fourth-quarter 2025 sales of US$636.2 million and full-year sales of US$2.52 billion, alongside higher quarterly and annual net income, while also completing two share repurchase programs totaling US$1.46 billion and filing a US$300.47 million shelf registration for 12,150,187 Class A shares tied to an ESOP offering. This combination of improving profitability despite slightly lower sales, sizeable buybacks, and a new employee share-related shelf...
NYSE:NATL
NYSE:NATLDiversified Financial

Assessing NCR Atleos (NATL) Valuation After Strong Recent Share Price Momentum

NCR Atleos (NATL) has drawn fresh attention after recent trading, with the stock closing at $48.06 and showing strong short term and past 3 months moves that stand out against its longer history. See our latest analysis for NCR Atleos. That recent burst of momentum, with a 7 day share price return of 18.7% and 90 day share price return of 28.4% at a last close of US$48.06, sits against a much stronger 1 year total shareholder return of 87.1%. This hints that sentiment around NCR Atleos has...